Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms
| Autor: | Nicholas J. Short, Hagop M. Kantarjian, Elias Jabbour |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty medicine.drug_class medicine.medical_treatment Hematopoietic stem cell transplantation Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Inotuzumab ozogamicin business.industry Ponatinib Hematology medicine.disease Chimeric antigen receptor Clinical trial Leukemia 030104 developmental biology chemistry 030220 oncology & carcinogenesis Blinatumomab business medicine.drug |
| Zdroj: | Leukemia. 35:3044-3058 |
| ISSN: | 1476-5551 0887-6924 |
| Popis: | In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes. With the development of the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin, the CD3-CD19 bispecific T-cell engager antibody blinatumomab, CD19 chimeric antigen receptor T-cell therapy, and the potent BCR-ABL1 tyrosine kinase inhibitor ponatinib, the outlook of ALL in both younger and older adults has substantially improved. The availability of highly effective drugs raised important questions concerning the optimal combination and sequence of these agents, their incorporation into frontline regimens, and the role of hematopoietic stem cell transplantation. In this review, we discuss the rapidly evolving paradigms in the treatment of ALL, highlighting both established and effective regimens, as well as promising new therapies that are being evaluated in ongoing clinical trials. We specifically focus on novel combination regimens in both the frontline and salvage settings that are leading to new standards of care in the treatment of ALL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink